Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children

Lupus Science and Medicine

Volumn 1, Issue 1, 2014, Pages

  Brunner, Hermine I ^a   Klein Gitelman, Marisa S ^b   Zelko, Frank ^b,c   Beebe, Dean W ^a   Foell, Dirk ^d   Lee, Jiha ^a   Zaal, Ahmad ^a   Jones, Jordan ^a   Roebuck Spencer, Tresa ^e   Ying, Jun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CALGRANULIN A; CALGRANULIN B; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; GLYCOPROTEIN 1 ANTIBODY; LUPUS ANTICOAGULANT; METHOTREXATE; MYCOPHENOLATE MOFETIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2AB ANTIBODY; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PREDNISONE; PROTEIN S100B; RIBOSOMAL P ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; ATTENTION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXPLORATORY RESEARCH; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL CONCENTRATION; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RECEIVER OPERATING CHARACTERISTIC; RESPONSE TIME; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; VISION; WORKING MEMORY;

EID: 84929327841     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2014-000038     Document Type: Article

References (46)

1. Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 2010;28:61-73.
2. Sibbitt WL Jr, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002;29:1536-42.
3. Ruth N, Roebuck-Spencer T, Graham T, et al. Diagnosis of childhood-onset lupus neurocognitive impairment in a clinical setting: usefulness of computer based testing and self-report. Washington, DC: American College of Rheumatology, 2006.
4. Harel L, Sandborg C, Lee T, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006;33:1873-7.
5. Brunner HI, Ruth NM, German A, et al. Initial validation of the pediatric automated neuropsychological assessment metrics for childhood-onset systemic lupus erythematosus. Arthrit Rheum-Arthr 2007;57:1174-82.
6. Ross GS, Zelko F, Klein-Gitelman M, et al. A proposed framework to standardize the neurocognitive assessment of patients with pediatric systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:1029-33.
7. Brunner HI, Klein-Gitelman MS, Zelko F, et al. Validation of the pediatric automated neuropsychological assessment metrics in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013;65:372-81.
8. Luyendijk J, Steens SC, Ouwendijk WJ, et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 2011;63:722-32.
9. Brey RL. Neuropsychiatric lupus: clinical and imaging aspects. Bull NYU Hosp Jt Dis 2007;65:194-9.
10. Mostafa GA, Ibrahim DH, Shehab AA, et al. The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric systemic lupus erythematosus. J Neuroimmunol 2010;227:195-201.
11. Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
12. Brunner HI, Feldman BM, Bombardier C, et al. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999;42:1354-60.
13. Brunner H, Silverman E, To T, et al. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002;45:436-44.
14. Wechsler D. Wechsler abbreviated scale of intelligence: WASI. San Antonio, USA: Psychological Corporation, Harcourt Brace, 1999.
15. Kaufman AS, Kaufman NL. Kaufman assessment battery for children, Second Edition (KABC™-II). Circle Pines, MN: American Guidance Service, 2004.
16. Wechlser D. Wechsler intelligence scale for children. 4rth edn. San Antonio, TX: Harcourt Assessment, Inc, 2003.
17. Wechsler D. Wechsler adult intelligence scale. 4th edn. San Antonio, TX: NCS Pearson, 2008.
18. Adams W, Sheslow D. WRAML2: wide range assessment of memory and learning: Administration and technical manual. 2nd edn. Wilmington, DE: Wide Range, 2003.
19. Woodcock RW, Johnson MB, Mather N. Woodcock-Johnson tests of cognitive ability: standard and supplemental batteries: WJ-R Woodcock-Johnson psycho-educational battery-revised. Allen, Tex: DLM Teaching Resources, 1990.
20. Conners C. Conners' continuous performance test II. N. Tonawanda, NY: Multihealth Systems, Inc, 2002.
21. Kovacs M. The Children's Depression Inventory (CDI). Psychopharmacol Bull 1985;21:995-8.
22. Williams TS, Aranow C, Ross GS, et al. Neurocognitive impairment in childhood-onset systemic lupus erythematosus: measurement issues in diagnosis. Arthritis Care Res (Hoboken) 2011;63:1178-87.
23. Shimojima Y, Matsuda M, Gono T, et al. Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus. Clin Rheumatol 2005;24:469-75.
24. Hirohata S, Arinuma Y, Yanagida T, et al. Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther 2014;16:R77.
25. DeGiorgio LA, Konstantinov KN, Lee SC, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189-93.
26. Chapman J, Cohen-Armon M, Shoenfeld Y, et al. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999;8:127-33.
27. Aldar H, Lapa AT, Bellini B, et al. Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus. Lupus 2012;21:1225-31.
28. Engel S, Schluesener H, Mittelbronn M, et al. Dynamics of microglial activation after human traumatic brain injury are revealed by delayed expression of macrophage-related proteins MRP8 and MRP14. Acta Neuropathol 2000;100:313-22.
29. Sen J, Belli A. S100B in neuropathologic states: The CRP of the brain? J Neurosci Res 2007;85:1373-80.
30. Moroz OV, Burkitt W, Wittkowski H, et al. Both Ca2+ and Zn2+ are essential for S100A12 protein oligomerization and function. BMC Biochem 2009;10:11.
31. Foell D, Frosch M, Sorg C, et al. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004;344:37-51.
32. Jha MK, Suk K. Glia-based biomarkers and their functional role in the CNS. Expert Rev Proteomics 2013;10:43-63.
33. Suzuki M, Wiers KM, Klein-Gitelman MS, et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 2008;23:403-12.
34. Roy A. Estimating correlation coefficient between two variables with repeated observations using mixed effects model. Biom J 2006;48:286-301.
35. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44: 837-45.
36. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
37. Ainiala H, Hietaharju A, Dastidar P, et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum 2004;50:858-65.
38. Bosma GP, Rood MJ, Huizinga TW, et al. Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging. Arthritis Rheum 2000;43:2428-36.
39. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 58:1130-5.
40. Yoshio T, Hirata D, Onda K, et al. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 2005;32:34-9.
41. Hanly JG, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011;70:1726-32.
42. Lauvsnes MB, Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol 2012;259:622-9.
43. Sato T, Fujii T, Yokoyama T, et al. Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 2010;62:3730-40.
44. George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008;10:R97.
45. Fragoso-Loyo H, Cabiedes J, Atisha-Fregoso Y, et al. Utility of serum S100B protein for identification of central nervous system involvement in systemic lupus erythematosus. J Rheumatol 2010;37:2280-5.
46. Russell MD, Young AM, Karri SK. Biomarkers of Pediatric Brain Tumors. Front Pediatr 2013;1:7.